NDC 0078-0697 Promacta
Eltrombopag Olamine Powder, For Suspension Oral - View Dosage, Usage, Ingredients, Routes, UNII
Product Information
- 0078 - Novartis Pharmaceuticals Corporation
- 0078-0697 - Promacta
Product Characteristics
ORANGE (C48331)
BLUE (C48333)
PINK (C48328)
GS;NX3;25
GS;UFU;50
GS;FFS;75
Product Packages
NDC Code 0078-0697-61
Package Description: 1 CARTON in 1 KIT / 30 PACKET in 1 CARTON (0078-0697-23) / 1 POWDER, FOR SUSPENSION in 1 PACKET (0078-0697-19)
Product Details
What is NDC 0078-0697?
What are the uses for Promacta?
What are Promacta Active Ingredients?
Which are Promacta UNII Codes?
The UNII codes for the active ingredients in this product are:
- ELTROMBOPAG OLAMINE (UNII: 4U07F515LG)
- ELTROMBOPAG (UNII: S56D65XJ9G) (Active Moiety)
Which are Promacta Inactive Ingredients UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MANNITOL (UNII: 3OWL53L36A)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POVIDONE (UNII: FZ989GH94E)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
- SUCRALOSE (UNII: 96K6UQ3ZD4)
- XANTHAN GUM (UNII: TTV12P4NEE)
What is the NDC to RxNorm Crosswalk for Promacta?
- RxCUI: 1245001 - eltrombopag 12.5 MG Oral Tablet
- RxCUI: 1245001 - eltrombopag (as eltrombopag olamine) 12.5 MG Oral Tablet
- RxCUI: 1245003 - Promacta 12.5 MG Oral Tablet
- RxCUI: 1245003 - eltrombopag 12.5 MG Oral Tablet [Promacta]
- RxCUI: 1245003 - Promacta (as eltrombopag olamine) 12.5 MG Oral Tablet
Which are the Pharmacologic Classes for Promacta?
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Increased Megakaryocyte Maturation - [PE] (Physiologic Effect)
- Increased Platelet Production - [PE] (Physiologic Effect)
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- Thrombopoietin Receptor Agonist - [EPC] (Established Pharmacologic Class)
- Thrombopoietin Receptor Agonists - [MoA] (Mechanism of Action)
- UGT1A1 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A3 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A4 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A6 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A9 Inhibitors - [MoA] (Mechanism of Action)
- UGT2B15 Inhibitors - [MoA] (Mechanism of Action)
- UGT2B7 Inhibitors - [MoA] (Mechanism of Action)
* Please review the disclaimer below.
Patient Education
Eltrombopag
Eltrombopag is used to increase the number of platelets (cells that help the blood clot) to decrease the risk of bleeding in adults and children 1 year of age and older who have chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) and who have not been helped or cannot be treated with other treatments, including medications or surgery to remove the spleen. Eltrombopag is also used to increase the number of platelets in people who have hepatitis C (a viral infection that may damage the liver) so that they can begin and continue treatment with interferon (Peginterferon, Pegintron, others) and ribavirin (Rebetol). Eltrombopag is also used in combination with other medications to treat aplastic anemia (condition in which the body does not make enough new blood cells) in adults and children 2 years of age and older. It is also used to treat aplastic anemia in adults who have not been helped with other medications. Eltrombopag is used to increase the number of platelets enough to decrease the risk of bleeding in people with ITP or aplastic anemia, or to allow treatment with interferon and ribavirin in people with hepatitis C. However it is not used to increase the number of platelets to a normal level. Eltrombopag should not be used to treat people who have low numbers of platelets due to conditions other than ITP, hepatitis C, or aplastic anemia. Eltrombopag is in a class of medications called thrombopoietin receptor agonists. It works by causing the cells in the bone marrow to produce more platelets.
[Learn More]
* Please review the disclaimer below.
[1] What is the Non-Proprietary Name? - The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
[2] What is the Substance Name? - An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
[3] What kind of product is this? - Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
[4] What are the Administration Routes? - The translation of the route code submitted by the firm, indicating route of administration.
[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.
[6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
[8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.
[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.
[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".